A big valuation at float is no guarantee of ongoing investor support, as a look at the sector’s biggest IPOs reveals.
Roche is set to lose its crown as the largest oncology player to the newly merged Bristol-Myers Squelgene, while Astrazeneca is forecast to streak up the rankings.
Which deals accidentally brought in the biggest biopharma blockbusters? A new analysis by Vantage reveals all.
Only seven drug developers managed to float on Western exchanges in the third quarter, and new issues in October have struggled, with Biontech the latest example.
Megadeals flattered the biopharma M&A scene in the first half of 2019, but the numbers took a nose dive in the third-quarter.
The latest venture capital numbers suggest that 2019 will see a healthy amount raised, but the falling number of rounds could be a worry.
Daiichi Sankyo’s incredible stock market performance stands out amid the usual mixed bag of fallers and risers among biopharma’s mid- and small caps.
Non-US big biopharma stocks led the way in the third quarter, suggesting that those looking for investment gains would do best to search further afield.
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.